Catamaran Bio
Eugene Choi is currently the Associate Director, In Vitro Pharmacology at Catamaran Bio since August 2020. Previously, Eugene held positions at Unum Therapeutics and Novartis Institutes for BioMedical Research. Eugene's expertise lies in coordinating research activities, advancing pipeline projects, and developing novel technology platforms in the field of immunopharmacology. With a background in Molecular Epidemiology and Biology from Harvard University, Eugene brings a wealth of knowledge and experience to their current role.
Catamaran Bio
Catamaran Bio is a newly-formed biotechnology company funded by SV Health Investors. Catamaran is developing transformative off-the-shelf CAR-NK cell therapies.